Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by StockNews.com to Hold

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Thursday.

A number of other research firms have also recently weighed in on ASND. Wells Fargo & Company raised their price target on Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $173.00 price target on shares of Ascendis Pharma A/S in a report on Wednesday, May 15th. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Wedbush raised their price objective on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Finally, Citigroup lifted their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $176.88.

Ascendis Pharma A/S Trading Up 0.7 %

ASND stock opened at $130.41 on Thursday. The firm has a market cap of $7.59 billion, a P/E ratio of -13.57 and a beta of 0.54. Ascendis Pharma A/S has a 1-year low of $83.75 and a 1-year high of $161.00. The business’s 50 day moving average is $140.23 and its 200-day moving average is $131.61.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.91). Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 152.68%. The company had revenue of $103.11 million for the quarter, compared to analyst estimates of $85.72 million. Sell-side analysts forecast that Ascendis Pharma A/S will post -5.03 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at about $25,000. Private Ocean LLC acquired a new position in shares of Ascendis Pharma A/S in the 1st quarter valued at approximately $36,000. Quadrant Capital Group LLC grew its position in shares of Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after buying an additional 91 shares during the period. Finally, Signaturefd LLC lifted its stake in Ascendis Pharma A/S by 31.9% in the third quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 193 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.